Pediatric Living Donor Kidney Transplantation Under Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 4-Year Experience

    loading  Checking for direct PDF access through Ovid



Alemtuzumab has been used in off-label studies of solid organ transplantation.


We analyzed the first 42 pediatric consecutive living donor kidney transplantations under alemtuzumab pretreatment with tacrolimus monotherapy and subsequent spaced weaning. We focused especially on the causes of recipient death and graft loss and the characteristics of rejection.


Laparoscopic live-donor nephrectomy was associated with no mortality and no delayed graft function. The actuarial 1, 2, 3, and 4 years patient and graft survivals were 97.6% and 97.6%, 93.5% and 85.4%, 93.5% and 85.4%, and 93.5% and 85.4%, respectively. The incidence of cumulative acute cellular rejection (ACR) at 1, 2, 3, and 4 years was 0%, 2.4%, 4.8%, and 4.8%, respectively. The mean serum creatinine (mg/dL) and glomerular filtration rate (mL/min/1.73 m2) at 1, 2, and 3 years were 0.8±0.4 and 94.0±36.8, 0.9±0.4 and 79.6±31.9, and 0.9±0.4 and 95.0±21.7, respectively. Two (4.7%) recipients had ACR, and both Banff 1a ACRs were steroid sensitive. No patients had antibody-mediated rejection. Weaning to spaced dose (qod or less) tacrolimus monotherapy was attempted in 16 (38%) and was successful in 12 (26%) patients. All patients are currently steroid free. There was no tissue invasive cytomegalovirus disease or infection, no BK/polyoma viral nephropathy, and no posttransplant proliferative disease.


This experience confirms the 4-year safety and efficacy of this approach in pediatric recipients.

Related Topics

    loading  Loading Related Articles